Total Clarity Wealth Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Total Clarity Wealth Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-350	Closed	-$8K	–	1027
2022 Q2	$8K	Buy	+350	New	+$7.8K	﹤0.01%	738
2022 Q1	–	Sell	-1,003	Closed	-$46K	–	966
2021 Q4	$46K	Sell	1,003 -319	-24%	-$21.5K	0.02%	424
2021 Q3	$110K	Buy	+1,322	New	+$109K	0.05%	292
2021 Q2	–	Sell	-1,553	Closed	-$258K	–	794
2021 Q1	$258K	Buy	+1,553	New	+$205K	0.15%	145

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $4.53B AUM 21.1% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Total Clarity Wealth Management's ONCT Position: Q3 2022 in Review

Total Clarity Wealth Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 350 shares — an estimated $8K sold.

Total Clarity Wealth Management first reported a position in ONCT in Q1 2021 and held it in 4 quarters. The position peaked at $258K in Q1 2021. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

Total Clarity Wealth Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Total Clarity Wealth Management sold 350 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $8K.
Total Clarity Wealth Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Total Clarity Wealth Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $258K in Q1 2021.
61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Total Clarity Wealth Management's 13F filing for Q3 2022, filed 4 Nov 2022.